use of type c natriuretic peptide variants to treat skeletal dysplasia

摘要

The present disclosure provides for the use of c-type natriuretic peptide (cnp) variants and novel pharmaceutical compositions and formulations comprising cnp-variant peptides for the treatment of skeletal dysplasia, one or more symptoms of skeletal dysplasia, such as long bone growth or rate of growth and other disorders with a symptom or component associated with skeletal dysplasia and / or cnp.